Musical Chairs: Lilly Leadership Changes Underscore Confidence In Donanemab Accelerated Approval
Company To Break Neuroscience Out Of Bio-Medicines Group
Oncology leader Anne White will oversee neuroscience and pain, while Bio-Medicines head Ilya Yuffa will take over for retiring Lilly International president; Loxo CEO will oversee entire oncology business.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: senior level changes at Lilly; mRNA COVID vaccines and booster shots; GSK and Sanofi deal with a changed vaccines landscape; a look ahead at new drugs for hematological malignancies; and a huge fundraising in China for an mRNA specialist.
Topline results suggest lebrikizumab could outshine Sanofi’s Dupixent on safety and itch reduction in atopic eczema, but a direct comparison study is likely required to drive the message home.
The upcoming filing of Lilly's Alzheimer's antibody donanemab dominated the company's second quarter call. Lilly is also developing a new blood test to confirm diagnosis and a second-generation antibody.